Publications by authors named "Tiny Schaap"
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study.
Eur J Drug Metab Pharmacokinet
July 2023
Article Synopsis
- Adalimumab underdosing can lead to ineffective treatment for rheumatic and inflammatory bowel diseases, prompting a study to forecast its concentrations early in therapy using population pharmacokinetic modeling.
- A literature search identified pharmacokinetic models, and patient samples were analyzed to predict steady state levels of adalimumab after the first dose, evaluating predictive performance through error metrics.
- The study included 36 patients, showing a 75% concordance between predicted and actual drug levels, and confirmed that early measurements can effectively predict future drug concentrations during treatment initiation.
Article Synopsis
- This study compares two methods of measuring infliximab (IFX) levels in children with inflammatory bowel disease (PIBD): traditional venipuncture and a more patient-friendly alternative called dried blood sampling (DBS) using a finger prick.
- It found that both methods produced similar results, with a strong correlation between venous serum levels and DBS measurements, indicating DBS is accurate.
- The study suggests DBS could be a viable option to regularly monitor IFX levels in pediatric patients, enhancing their comfort during treatment.
Article Synopsis
- The study aimed to evaluate the safety of monoclonal antibodies (MAbs) for breastfed infants when their mothers received these treatments during pregnancy or lactation.
- Researchers analyzed data from 23 patients, focusing on their health outcomes and the concentration of antibodies in breast milk and infants after one year.
- Findings indicated no major negative effects on infant health or development linked to MAb exposure through breast milk, although some infants had lower birth weights and more hospital visits if exposed to natalizumab in late pregnancy.
Article Synopsis
- Adalimumab (ADL) is an anti-TNF treatment for inflammatory bowel disease (IBD), and higher drug levels correlate with better patient outcomes.* -
- A study compared serum ADL levels from traditional blood draws to levels from dried blood samples (DBSs) collected at home, finding a high correlation for professional samples and a moderate one for home samples.* -
- Results suggest that using DBSs for at-home testing can effectively help monitor and adjust ADL therapy in everyday clinical practice.*
Article Synopsis
- Therapeutic drug monitoring (TDM) of infliximab (IFX) for patients with inflammatory bowel disease (IBD) can be improved using dried blood samples (DBS) taken at home, enabling quicker dose adjustments.
- A study compared DBS results from 40 IBD patients with traditional serum samples and found a very high correlation between them, indicating that DBS is a reliable measurement method.
- The research suggests that home sampling of DBS can lead to timely IFX dosage modifications, ultimately enhancing patient care and treatment effectiveness.
Article Synopsis
- - The study explores using the Mitra microsampler as an alternative to dried blood spot collection for monitoring biopharmaceutical concentrations, particularly therapeutic drugs.
- - Researchers tested various therapeutic monoclonal antibodies in whole blood using both the Mitra microsampler and filter paper, analyzing concentrations with specific ELISAs.
- - Results showed effective recovery rates for several therapeutic antibodies after storage for up to one month, establishing protocols for estimating drug concentrations from capillary blood samples.
Aims: Development of a self-sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. The aim of this study was to compare adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases.
Methods: In this cross-sectional study, 161 consecutive patients were included.